Here, we report the efficacy and safety of a prospective multicenter trial evaluating a new combination regimen, anlotinib plus icotinib, as the first-line treatment of EGFR mutation-positive advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.